ObjectiveTo systematically evaluate the clinical efficacy of systemic antibiotic combined with non-surgical periodontal therapy for aggressive periodontitis. MethodsWe searched PubMed, EMbase, The Cochrane Library, WanFang Data, CBM, VIP and CNKI databases from inception to January, 2016, to collect randomized controlled trials (RCTs) about non-surgical periodontal therapy combined with systemic antibiotics for aggressive periodontitis. Two reviewers independently screened literature, extracted data and evaluated the bias risk of included studies. Then meta-analysis was performed using RevMan 5.3 software. ResultsA total of 8 RCTs involving 236 patients were included. The results of meta-analysis showed, compared with non-surgical periodontal therapy alone, non-surgical periodontal therapy combined with systemic antibiotics showed a significant additional probing depth reduction at 3-, 6- and 12 months follow-up (MD=0.33, 95%CI 0.25 to 0.41, P<0.00001; MD=0.53, 95%CI 0.44 to 0.62, P<0.00001; MD=0.52, 95%CI 0.23 to 0.81, P=0.0004), and a significant clinical attachment gain at 3-, 6- and 12 months follow-up (MD=0.43, 95%CI 0.30 to 0.56, P<0.00001; MD=0.44, 95%CI 0.33 to 0.55, P<0.00001; MD=0.43, 95%CI 0.20 to 0.65, P=0.0002). ConclusionCurrent evidence shows that the treatment of patients with aggressive periodontitis, systemic antibiotic (Metronidazole and Amoxicillin) combined with non-surgical periodontal therapy has a significant additional effect than non-surgical therapy alone. However, because of the limitation of quality and quantity of included studies, the above conclusion still needs to be further proved by conducting more high-quality and large-scale RCTs.
Icariin（ICA） is one of the main active ingredients in the Berberidaceae family Epimedium. It makes a variety of biological activities, such as promoting bone formation, antibacterial and anti-inflammatory, and regulating immunity. Periodontitis is a chronic inflammatory disease that is present in the soft and hard tissues of the periodontium. The ultimate goals of its treatment are the reconstruction of periodontal tissues and bone defect repairing. At present, conventional treatment of periodontitis fails to achieve the ideal periodontal tissue regeneration. In recent years, the rapid development of tissue engineering technology has brought new ideas for the treatment of periodontal disease and bone defect repairing. Because of its anti-inflammatory and osteogenic effects, ICA has great potential for the treatments of periodontitis and bone defect repairing. This paper summarizes the effect and the molecular mechanism of ICA in the treatment of periodontitis and bone defect repairing, and discusses its application prospect as a drug for periodontal adjuvant therapy. This paper aims to provide a theoretical basis for the research and application of ICA in periodontitis treatment and bone defect repairing.
Polycystic ovary syndrome (PCOS) is a complex and heterogeneous common endocrine disease, and periodontitis is a chronic infectious immune inflammatory disease caused by dental plaque. In recent years, a large number of studies have shown that PCOS and periodontitis may be related, but the pathological mechanism is still unclear. Therefore, this article reviews the correlation between PCOS and periodontitis and the possible biological mechanisms of their mutual influence, in order to provide a theoretical basis for the prevention and treatment of periodontal disease in patients with PCOS.